Company: STAA
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058174
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 19
---
 to oversee the discharge of the responsibilities of the Board relating to the Company’s director nominations process and procedures, developing and maintaining the Company's corporate governance policies, and any related matters required by the federal securities laws, as set forth in the Committee’s written charter. In 2024, the Board conducted a review of its committee charters and approved updates to improve clarity and to better align with best practices. In accordance with its written charter, as revised, the Nominating and Governance Committee is responsible for the following: • identifying and evaluating individuals qualified to become directors, consistent with criteria approved by the Board (described in our Corporate Governance Guidelines, which is available on our website at http://staar.com , under “Investors-Investor Resources & FAQs-Governance Documents”); • recommending the director nominees to be selected by the Board for election at the next annual meeting of shareholders or to fill vacancies; • reviewing best practices in corporate governance, and recommending to the Board improvements in corporate governance that may be applicable to STAAR, including sustainability matters; • overseeing the Board evaluation and assessment process; and • recommending the composition and leadership of the Board Committees. The Nominating and Governance Committee is currently comprised of Elizabeth Yeu, M.D. (Chair), Louis E. Silverman, and Lilian Y. Zhou. During 2024, Stephen C. Farrell, Wei Jiang, Aimee S. Weisner, and K. Peony Yu, M.D. also served on the Nominating and Governance Committee. Dr. Yu served on the Committee until June 2024, at which time her term as a director expired at the 2024 annual meeting of shareholders. Mr. Farrell stepped down from the Committee in February 2025 in connection with his appointment as Chief Executive Officer. Ms. Weisner stepped down from the Nominating and Governance Committee in April 2025. In addition, Mr. Jiang stepped down from the Committee in April 2025, in connection with our engagement of Mr. Jiang to serve as a special strategic advisor to our Asia Pacific business. As a result of this engagement, the Board concluded that Mr. Jiang was no longer independent under the Nasdaq rules, and he stepped down from the Committee. Each current member of the Nominating and Governance Committee is independent under the Nasdaq rules, and each former member of the Committee qualified as independent during the time they served on the Committee. During 2024, the Nominating and Governance Committee met four times.